文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺癌患者髋关节假体放疗诱导毒性分析

Radiotherapy-induced toxicity in prostate cancer patients with hip prostheses.
PubMed 文献 · Radiat Oncol · 2022-01-17

本研究分析双侧髋关节假体前列腺癌患者接受固定野调强放疗(IMRT)的急性和晚期毒性,并与正常髋关节对照组比较。结果显示两组泌尿生殖(GU)和胃肠道(GI)毒性发生率无显著差异;但假体组IMRT计划膀胱和直肠剂量体积直方图(DVH)显著更高,采用容积旋转调强放疗(VMAT)再计划可显著降低危及器官剂量,同时保持靶区覆盖良好。

要点

  • 双侧髋关节假体前列腺癌患者IMRT后急性和晚期GU毒性发生率与对照组相似。
  • G2+晚期GI毒性发生率假体组31% vs 对照组14%(p=0.14),差异未达统计学显著。
  • 假体组IMRT计划中膀胱和直肠DVH显著高于对照组,VMAT再计划可显著降低危及器官剂量。

核心结论

  • 双侧髋关节假体患者与对照组之间GU和GI毒性发生率无显著差异。
  • 假体患者IMRT计划的膀胱和直肠DVH显著更高。
  • 采用VMAT技术再计划可显著降低危及器官剂量,同时保持计划靶区覆盖良好。

研究设计与样本

  • 研究纳入前列腺癌患者,假体组17例,对照组50例。
  • 假体组接受固定野IMRT,对照组为正常髋关节患者。
  • 毒性评估采用常见不良事件评价标准第5.0版(CTCAE v5.0),G2+毒性发生率比较采用Fisher精确检验,剂量体积直方图(DVH)和危及器官平均剂量比较采用符号秩检验。

主要发现

  • 急性和晚期GU毒性在假体组与对照组间相似。
  • G2+晚期GI毒性发生率假体组31% vs 对照组14%(p=0.14)。
  • 假体组IMRT与对照组在多个中间剂量水平的危及器官DVH上存在显著差异(p<0.05)。
  • 直肠平均剂量差异显著(p<0.001),膀胱平均剂量无差异(p=0.08)。
  • VMAT再计划显著降低危及器官剂量,同时保持计划靶区覆盖良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute and late toxicity was analysed for prostate cancer patients with bilateral hip prostheses, who received fixed field intensity modulated radiotherapy (IMRT). The aims were (1) to establish whether toxicity rates differed from those of a control group with normal hips, (2) to develop a volumetric modulated arc therapy (VMAT) approach for patients with prostheses and (3) to compare doses to bladder and rectum for the control group, prostheses group and VMAT replans for the prostheses group. METHODS: Genitourinary (GU) and gastrointestinal (GI) toxicity was scored using Common Terminology Criteria for Adverse Events version 5.0. The incidence of grade 2 or worse (G2+) toxicity was compared using Fisher's exact test. Dose volume histograms (DVHs) and mean doses to organs at risk (OARs) were compared using signed rank tests. RESULTS: There were 17 patients in the prostheses group and 50 in the control group. Acute and late GU toxicity was similar. G2+ late GI toxicity incidence was 31% for the prostheses group and 14% for the control group (p = 0.14). Significant differences (p < 0.05) were seen between the OAR DVHs of the prostheses group who had IMRT and the control group for a range of intermediate doses. The rectum mean dose was significantly different (p < 0.001), but no difference was seen for the bladder mean dose (p = 0.08). CONCLUSIONS: No significant differences were seen in GU and GI toxicity incidence between patients with bilateral hip prostheses and a control group. The DVHs for bladder and rectum were significantly higher for patients with prostheses planned with IMRT. Replanning using a VMAT technique significantly reduced doses to the OARs, whilst maintaining good planning target volume coverage.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fischer AM, Hoskin PJ. Radiotherapy-induced toxicity in prostate cancer patients with hip prostheses. Radiat Oncol. 2022. PMID: 35039065. doi:10.1186/s13014-021-01975-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。